pioglitazone has been researched along with Dyslipidemias in 43 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
Excerpt | Relevance | Reference |
---|---|---|
" After 12 weeks' treatment, the pioglitazone group showed a highly significant reduction in body weight (83±10." | 9.24 | Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia. ( Akhtar, L; Hussain, M; Shad, MN, 2017) |
" A total of 522 patients with hypertension and/or dyslipidemia who had one or more silent cerebral infarcts, advanced carotid atherosclerosis or microalbuminuria at baseline were randomly treated with (n=254) or without pioglitazone (n=268) and observed for a medium of 672 days." | 9.19 | Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study. ( Kawamori, R; Kitagawa, K; Kitakaze, M; Matsuhisa, M; Matsumoto, M; Onuma, T; Watada, H; Yamasaki, Y; Yamazaki, T; Yoshii, H, 2014) |
" We studied the effects of pioglitazone (PIO) and rosiglitazone (ROSI) treatments on serum lipoprotein particle concentrations and sizes in type 2 diabetic patients with dyslipidemia." | 9.12 | Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. ( Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Tan, MH; Zagar, AJ, 2007) |
"The purpose of this work was to compare the influences of sulforaphane (SFN) to those of the standard insulin sensitizer pioglitazone (PIO) on high fructose diet (HFrD)-induced insulin resistance, dyslipidemia, hepatosteatosis, and vascular dysfunction in rats." | 7.91 | Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats. ( Gameil, NM; Shawky, NM; Shehatou, GSG; Suddek, GM, 2019) |
" Pioglitazone treatment (3 mg/kg body weight/d for 6 weeks), a peroxisome proliferator-activated receptor γ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent benefits." | 7.77 | Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. ( Cheng, H; Ding, Y; Han, C; Hou, N; Huang, PL; Li, C; Li, K; Liu, N; Liu, Y; Mao, J; Raab, S; Sebokova, E; Shang, S; Song, Z; Wang, H; Wang, J; Xue, L; Zhang, H; Zhang, R; Zhang, X; Zhang, Y; Zheng, W; Zhu, T, 2011) |
" Baseline parameters came from a multi-center, double-blind trial comparing lipid and glycemic effects of pioglitazone (n = 400) and rosiglitazone (n = 402) among individuals with T2DM and untreated dyslipidemia." | 7.74 | Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. ( Baran, RW; Minshall, ME; Pandya, BJ; St Charles, M; Tunis, SL, 2008) |
" The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 7.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
"Dyslipidemia in patients with type 2 diabetes is characterized by elevated triglyceride levels, decreased high-density lipoprotein (HDL) cholesterol, and a predominance of small dense low-density lipoprotein (LDL) particles." | 6.76 | PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. ( Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D, 2011) |
"Treatment with pioglitazone, BCP, BCP + CB2R antagonist, AM630, or BCP + PPAR-γ antagonist, BADGE was started from the 9th week and continued till the 12th week." | 5.51 | Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: Involvement of CB2 and PPAR-γ receptors. ( El-Fayoumi, HM; Mahmoud, MF; Youssef, DA, 2019) |
"Biochemical markers of NAFLD worsened over time." | 5.40 | Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. ( Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR, 2014) |
" After 12 weeks' treatment, the pioglitazone group showed a highly significant reduction in body weight (83±10." | 5.24 | Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia. ( Akhtar, L; Hussain, M; Shad, MN, 2017) |
"Fenofibrate is a peroxisome proliferator-activated receptor-α that has been clinically used to treat dyslipidemia and insulin resistance." | 5.19 | Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue. ( Chen, M; Deng, D; Fang, Z; Hu, H; Luo, L; Wang, Y; Xu, M, 2014) |
" A total of 522 patients with hypertension and/or dyslipidemia who had one or more silent cerebral infarcts, advanced carotid atherosclerosis or microalbuminuria at baseline were randomly treated with (n=254) or without pioglitazone (n=268) and observed for a medium of 672 days." | 5.19 | Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study. ( Kawamori, R; Kitagawa, K; Kitakaze, M; Matsuhisa, M; Matsumoto, M; Onuma, T; Watada, H; Yamasaki, Y; Yamazaki, T; Yoshii, H, 2014) |
" In this study, we administered pioglitazone and pitavastatin for 16 weeks to 18 patients who had type 2 diabetes complicated by dyslipidemia and then investigated the influence of these 2 drugs on MDA-LDL(i." | 5.15 | [Study of MDA-LDL by pioglitazone and pitavastatin in patients with type 2 diabetes]. ( Hayashi, S; Taguchi, A, 2011) |
"Three-month treatment with pioglitazone improved glycaemic control, homeostasis model assessment for insulin resistance (HOMA), dyslipidaemia and liver function tests in association with a marked increase in serum HMW adiponectin level." | 5.14 | Withdrawal of pioglitazone in patients with type 2 diabetes mellitus. ( Asano, T; Hiramatsu, S; Iida, M; Iwase, M; Ogo, A; Sakai, Y; Sasaki, N; Yoshizumi, H, 2010) |
" We studied the effects of pioglitazone (PIO) and rosiglitazone (ROSI) treatments on serum lipoprotein particle concentrations and sizes in type 2 diabetic patients with dyslipidemia." | 5.12 | Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. ( Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Tan, MH; Zagar, AJ, 2007) |
" This study compared the efficacy of tesaglitazar with that of pioglitazone as adjunctive therapy to atorvastatin in subjects with abdominal obesity and dyslipidemia." | 5.12 | The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin. ( Lindberg, MB; Ohman, KP; Ose, L; Retterstøl, K; Svensson, M; Tonstad, S, 2007) |
"This paper reviewed the effects of pioglitazone and rosiglitazone on atherogenic diabetic dyslipidemia, in particular on small dense low-density lipoprotein particles." | 4.84 | The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance? ( Berneis, K; Christ, ER; Rini, GB; Rizzo, M; Spinas, GA, 2008) |
"Pioglitazone is an antihyperglycaemic agent that, in the presence of insulin resistance, increases hepatic and peripheral insulin sensitivity, thereby inhibiting hepatic gluconeogenesis and increasing peripheral and splanchnic glucose uptake." | 4.83 | Pioglitazone: a review of its use in type 2 diabetes mellitus. ( Easthope, S; Keating, GM; Plosker, GL; Robinson, DM; Waugh, J, 2006) |
" Pioglitazone, an antidiabetic agent that acts primarily by decreasing insulin resistance, improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis." | 4.82 | The metabolic basis of atherogenic dyslipidemia. ( Vinik, AI, 2005) |
"The purpose of this work was to compare the influences of sulforaphane (SFN) to those of the standard insulin sensitizer pioglitazone (PIO) on high fructose diet (HFrD)-induced insulin resistance, dyslipidemia, hepatosteatosis, and vascular dysfunction in rats." | 3.91 | Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats. ( Gameil, NM; Shawky, NM; Shehatou, GSG; Suddek, GM, 2019) |
" Pioglitazone treatment (3 mg/kg body weight/d for 6 weeks), a peroxisome proliferator-activated receptor γ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent benefits." | 3.77 | Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. ( Cheng, H; Ding, Y; Han, C; Hou, N; Huang, PL; Li, C; Li, K; Liu, N; Liu, Y; Mao, J; Raab, S; Sebokova, E; Shang, S; Song, Z; Wang, H; Wang, J; Xue, L; Zhang, H; Zhang, R; Zhang, X; Zhang, Y; Zheng, W; Zhu, T, 2011) |
" Baseline parameters came from a multi-center, double-blind trial comparing lipid and glycemic effects of pioglitazone (n = 400) and rosiglitazone (n = 402) among individuals with T2DM and untreated dyslipidemia." | 3.74 | Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. ( Baran, RW; Minshall, ME; Pandya, BJ; St Charles, M; Tunis, SL, 2008) |
" The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 3.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
"Statin therapy is safe in patients with prediabetes/T2DM and NASH." | 2.84 | Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. ( Bril, F; Cusi, K; Hecht, J; Lomonaco, R; Orsak, B; Portillo Sanchez, P; Tio, F, 2017) |
"Type 2 diabetes is a major risk factor for chronic kidney disease, which substantially increases the risk of cardiovascular disease mortality." | 2.79 | Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study. ( Hanefeld, M; Herz, M; Lincoff, AM; Malmberg, K; Meyer-Reigner, S; Mudie, N; Ruilope, L; Viberti, G; Wieczorek Kirk, D, 2014) |
"Dyslipidemia in patients with type 2 diabetes is characterized by elevated triglyceride levels, decreased high-density lipoprotein (HDL) cholesterol, and a predominance of small dense low-density lipoprotein (LDL) particles." | 2.76 | PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. ( Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D, 2011) |
"Though gout is more prevalent in men than women, it remains unclear whether gender influences risk factors for incident gout." | 2.61 | Gender-specific risk factors for gout: a systematic review of cohort studies. ( Belcher, J; Evans, PL; Hay, CA; Mallen, CD; Prior, JA; Roddy, E, 2019) |
"Statins have a primary role in the treatment of dyslipidemia in people with type 2 diabetes, defined as triglyceride levels >200 mg/dl and HDL cholesterol levels <40 mg/dL." | 2.55 | Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. ( Anabtawi, A; Miles, JM; Moriarty, PM, 2017) |
"Nonalcoholic fatty liver disease is the most common cause of liver dysfunction in the western world because of its close association with obesity, insulin resistance and dyslipidaemia." | 2.52 | Nonalcoholic fatty liver disease: new treatments. ( Anstee, QM; Day, CP; Hardy, T, 2015) |
"Treatment with Rosiglitazone should be reconsidered because of a potential cardiovascular risk." | 2.44 | [Therapy with glitazones--a risk for cardiovascular disease?]. ( Erdmann, E; Hoppe, UC; Michels, G; Rottlaender, D, 2007) |
"Treatment with pioglitazone, BCP, BCP + CB2R antagonist, AM630, or BCP + PPAR-γ antagonist, BADGE was started from the 9th week and continued till the 12th week." | 1.51 | Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: Involvement of CB2 and PPAR-γ receptors. ( El-Fayoumi, HM; Mahmoud, MF; Youssef, DA, 2019) |
"Biochemical markers of NAFLD worsened over time." | 1.40 | Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. ( Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR, 2014) |
"Pioglitazone has been shown to significantly reduce cardiovascular adverse outcomes, while preliminary data on IBTs are very encouraging as well." | 1.39 | Non-glycemic effects of pioglitazone and incretin-based therapies. ( Avogaro, A; Montalto, G; Rizvi, AA; Rizzo, M, 2013) |
"Fenofibrate treatment significantly improved lipoprotein metabolism toward a less atherogenic phenotype but did not affect insulin sensitivity." | 1.33 | PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. ( Fiévet, C; Fruchart, JC; Hennuyer, N; Mezdour, H; Staels, B; Tailleux, A; Torpier, G, 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 18 (41.86) | 29.6817 |
2010's | 23 (53.49) | 24.3611 |
2020's | 2 (4.65) | 2.80 |
Authors | Studies |
---|---|
Liu, W | 1 |
Liu, K | 1 |
Wood, HB | 1 |
McCann, ME | 1 |
Doebber, TW | 1 |
Chang, CH | 1 |
Akiyama, TE | 1 |
Einstein, M | 1 |
Berger, JP | 1 |
Meinke, PT | 1 |
Aggarwal, H | 1 |
Pathak, P | 1 |
Kumar, Y | 1 |
Jagavelu, K | 1 |
Dikshit, M | 1 |
Krishnappa, M | 1 |
Patil, K | 1 |
Parmar, K | 1 |
Trivedi, P | 1 |
Mody, N | 1 |
Shah, C | 1 |
Faldu, K | 1 |
Maroo, S | 1 |
Parmar, D | 1 |
Yamada, T | 1 |
Hiraoka, E | 1 |
Miyazaki, T | 1 |
Sato, J | 1 |
Ban, N | 1 |
Anabtawi, A | 1 |
Moriarty, PM | 1 |
Miles, JM | 1 |
Bril, F | 1 |
Portillo Sanchez, P | 1 |
Lomonaco, R | 1 |
Orsak, B | 1 |
Hecht, J | 1 |
Tio, F | 1 |
Cusi, K | 1 |
Hussain, M | 1 |
Shad, MN | 1 |
Akhtar, L | 1 |
Hirano, T | 1 |
Youssef, DA | 1 |
El-Fayoumi, HM | 1 |
Mahmoud, MF | 1 |
Shawky, NM | 1 |
Shehatou, GSG | 1 |
Suddek, GM | 1 |
Gameil, NM | 1 |
Corey, KE | 1 |
Wilson, LA | 1 |
Altinbas, A | 1 |
Yates, KP | 1 |
Kleiner, DE | 1 |
Chung, RT | 1 |
Krauss, RM | 1 |
Chalasani, N | 2 |
Evans, PL | 1 |
Prior, JA | 1 |
Belcher, J | 1 |
Hay, CA | 1 |
Mallen, CD | 1 |
Roddy, E | 1 |
Rizzo, M | 2 |
Avogaro, A | 1 |
Montalto, G | 1 |
Rizvi, AA | 1 |
Chen, M | 1 |
Deng, D | 1 |
Fang, Z | 1 |
Xu, M | 1 |
Hu, H | 1 |
Luo, L | 1 |
Wang, Y | 1 |
Riche, DM | 1 |
Fleming, JW | 1 |
Malinowski, SS | 1 |
Black, CA | 1 |
Miller, KH | 1 |
Wofford, MR | 1 |
Yoshii, H | 1 |
Onuma, T | 1 |
Yamazaki, T | 1 |
Watada, H | 1 |
Matsuhisa, M | 1 |
Matsumoto, M | 1 |
Kitagawa, K | 1 |
Kitakaze, M | 1 |
Yamasaki, Y | 1 |
Kawamori, R | 1 |
Ibáñez, L | 1 |
Ong, KK | 1 |
López-Bermejo, A | 1 |
Dunger, DB | 1 |
de Zegher, F | 1 |
Perségol, L | 1 |
Duvillard, L | 1 |
Monier, S | 1 |
Brindisi, MC | 1 |
Bouillet, B | 1 |
Petit, JM | 1 |
Vergès, B | 2 |
Ruilope, L | 1 |
Hanefeld, M | 1 |
Lincoff, AM | 1 |
Viberti, G | 1 |
Meyer-Reigner, S | 1 |
Mudie, N | 1 |
Wieczorek Kirk, D | 1 |
Malmberg, K | 1 |
Herz, M | 1 |
Hardy, T | 1 |
Anstee, QM | 1 |
Day, CP | 1 |
Liu, HJ | 1 |
Zhang, CY | 1 |
Song, F | 1 |
Xiao, T | 1 |
Meng, J | 1 |
Zhang, Q | 1 |
Liang, CL | 1 |
Li, S | 1 |
Wang, J | 2 |
Zhang, B | 1 |
Liu, YR | 1 |
Sun, T | 1 |
Zhou, HG | 1 |
Derosa, G | 1 |
Salvadeo, SA | 1 |
Christ, ER | 1 |
Rini, GB | 1 |
Spinas, GA | 1 |
Berneis, K | 1 |
Tunis, SL | 1 |
Minshall, ME | 1 |
St Charles, M | 1 |
Pandya, BJ | 1 |
Baran, RW | 1 |
Vuppalanchi, R | 1 |
Iwase, M | 1 |
Asano, T | 1 |
Sasaki, N | 1 |
Yoshizumi, H | 1 |
Hiramatsu, S | 1 |
Sakai, Y | 1 |
Ogo, A | 1 |
Iida, M | 1 |
Taguchi, A | 1 |
Hayashi, S | 1 |
Pfützner, A | 1 |
Schöndorf, T | 1 |
Tschöpe, D | 2 |
Lobmann, R | 1 |
Merke, J | 1 |
Müller, J | 1 |
Lehmann, U | 1 |
Fuchs, W | 1 |
Forst, T | 2 |
Zhang, X | 1 |
Zhang, R | 1 |
Raab, S | 1 |
Zheng, W | 1 |
Liu, N | 1 |
Zhu, T | 1 |
Xue, L | 1 |
Song, Z | 1 |
Mao, J | 1 |
Li, K | 1 |
Zhang, H | 1 |
Zhang, Y | 1 |
Han, C | 1 |
Ding, Y | 1 |
Wang, H | 1 |
Hou, N | 1 |
Liu, Y | 1 |
Shang, S | 1 |
Li, C | 1 |
Sebokova, E | 1 |
Cheng, H | 1 |
Huang, PL | 1 |
Shinohara, Y | 1 |
Hennuyer, N | 1 |
Tailleux, A | 1 |
Torpier, G | 1 |
Mezdour, H | 1 |
Fruchart, JC | 1 |
Staels, B | 1 |
Fiévet, C | 1 |
Betteridge, DJ | 1 |
Waugh, J | 1 |
Keating, GM | 1 |
Plosker, GL | 1 |
Easthope, S | 1 |
Robinson, DM | 1 |
Vinik, AI | 1 |
Trogan, E | 1 |
Feig, JE | 1 |
Dogan, S | 1 |
Rothblat, GH | 1 |
Angeli, V | 1 |
Tacke, F | 1 |
Randolph, GJ | 1 |
Fisher, EA | 1 |
Li, PP | 1 |
Shan, S | 1 |
Chen, YT | 1 |
Ning, ZQ | 1 |
Sun, SJ | 1 |
Liu, Q | 1 |
Lu, XP | 1 |
Xie, MZ | 1 |
Shen, ZF | 1 |
Berhanu, P | 1 |
Kipnes, MS | 1 |
Khan, MA | 2 |
Perez, AT | 2 |
Kupfer, SF | 1 |
Spanheimer, RC | 1 |
Demissie, S | 1 |
Fleck, PR | 1 |
Yoshiuchi, I | 1 |
Itoh, N | 1 |
Nakano, M | 1 |
Tatsumi, C | 1 |
Yokoyama, K | 1 |
Matsuyama, T | 1 |
Deeg, MA | 1 |
Buse, JB | 1 |
Goldberg, RB | 1 |
Kendall, DM | 1 |
Zagar, AJ | 1 |
Jacober, SJ | 1 |
Tan, MH | 1 |
Tonstad, S | 1 |
Retterstøl, K | 1 |
Ose, L | 1 |
Ohman, KP | 1 |
Lindberg, MB | 1 |
Svensson, M | 1 |
Comaschi, M | 1 |
Corsi, A | 1 |
Di Pietro, C | 1 |
Bellatreccia, A | 1 |
Mariz, S | 1 |
Rottlaender, D | 1 |
Michels, G | 1 |
Erdmann, E | 2 |
Hoppe, UC | 1 |
Eckert, S | 1 |
Lundershausen, R | 1 |
Scherbaum, WA | 1 |
Schnell, O | 1 |
Standl, E | 1 |
Schumm-Draeger, PM | 1 |
Walter, H | 1 |
Weber, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®[NCT01043029] | Phase 2 | 302 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study[NCT04081571] | 1,080 participants (Anticipated) | Observational | 2019-04-01 | Recruiting | |||
Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic Dyslipidemia[NCT00770653] | Phase 3 | 305 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
A Single-Arm, Open-Label, Multicenter Study Evaluating the Triglyceride Changes in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia Following Treatment Conversion From Rosiglitazone to Pioglitazone HCl in Combination With Stable Statin Therapy[NCT00672919] | Phase 4 | 305 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
Pioglitazone Versus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia[NCT00331487] | Phase 3 | 719 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The change between Adiponectin collected at week 24 or final visit and Adiponectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | μg/mL (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 6.79 |
Glimepiride 2 mg and Metformin 850 mg BID | 0.72 |
The change between Diastolic Blood Pressure measured at week 24 or final visit and Diastolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | mmHg (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | -1.3 |
Glimepiride 2 mg and Metformin 850 mg BID | -0.1 |
The change between the value of E-Selectin collected at week 24 or final visit and E-Selectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | ng/mL (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | -3.7 |
Glimepiride 2 mg and Metformin 850 mg BID | -0.5 |
The change between the 0.30 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | percent (Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 1.3 |
Glimepiride 2 mg and Metformin 850 mg BID | -0.4 |
The change between the 0.60 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | percent (Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 2.4 |
Glimepiride 2 mg and Metformin 850 mg BID | -0.5 |
The change between the 1.20 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | percent (Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 3.2 |
Glimepiride 2 mg and Metformin 850 mg BID | -1.1 |
The change between the 12.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | percent (Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 2.7 |
Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between the 3.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | percent (Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 3.3 |
Glimepiride 2 mg and Metformin 850 mg BID | -.15 |
The change between the 30.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | percent (Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 2.5 |
Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between the 6.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | percent (Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 3.1 |
Glimepiride 2 mg and Metformin 850 mg BID | -1.4 |
The change between the 60.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | percent (Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 2.7 |
Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between Fasting Glucose collected at week 24 or final visit and Fasting Glucose collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | mg/dL (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | -21.6 |
Glimepiride 2 mg and Metformin 850 mg BID | -21.1 |
The change between Fasting Intact Proinsulin collected at week 24 or final visit and Fasting Intact Proinsulin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | pmol/L (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | -5.18 |
Glimepiride 2 mg and Metformin 850 mg BID | -0.11 |
The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit and Glycosylated Hemoglobin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | mg/dL (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | -0.83 |
Glimepiride 2 mg and Metformin 850 mg BID | -0.95 |
The change between the value of High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at week 24 or final visit and High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | mg/L (Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | -0.87 |
Glimepiride 2 mg and Metformin 850 mg BID | 0.00 |
The change between the value of High Sensitivity C-reactive Protein collected at week 24 or final visit and High Sensitivity C-reactive Protein collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | mg/L (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | -0.21 |
Glimepiride 2 mg and Metformin 850 mg BID | -0.04 |
The change between HDL-Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | mg/dL (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 3.3 |
Glimepiride 2 mg and Metformin 850 mg BID | -0.4 |
The change between High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at week 24 or final visit and High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | mg/dL (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 0.1 |
Glimepiride 2 mg and Metformin 850 mg BID | 0.3 |
The change between Low-Density Lipoprotein Cholesterol collected at week 24 or final visit and Low-Density Lipoprotein Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | mg/dL (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 9.7 |
Glimepiride 2 mg and Metformin 850 mg BID | 11.2 |
The change between the value of Low-Density Lipoprotein Subfractions collected at week 24 or final visit and Low-Density Lipoprotein Subfractions collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | mg/dL (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 6.2 |
Glimepiride 2 mg and Metformin 850 mg BID | 6.1 |
The change between the value of Baseline in Matrix Metallo Proteinase-9 collected at week 24 or final visit and Baseline in Matrix Metallo Proteinase-9 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | ng/mL (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 31.4 |
Glimepiride 2 mg and Metformin 850 mg BID | 51.6 |
The change between the value of Nitrotyrosine collected at week 24 or final visit and Nitrotyrosine collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | nmol/L (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | -2.7 |
Glimepiride 2 mg and Metformin 850 mg BID | 32.5 |
The change between the value of Platelet Function by PFA 100 collected at week 24 or final visit and Platelet Function by PFA 100 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | sec (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | -30.3 |
Glimepiride 2 mg and Metformin 850 mg BID | -1.0 |
The change between the value of Soluble CD40 Ligand collected at week 24 or final visit and Soluble CD40 Ligand collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | pg/mL (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | -40.7 |
Glimepiride 2 mg and Metformin 850 mg BID | 102.4 |
The change between the value of Baseline in Soluble Intracellular Adhesion molecule at week 24 or final visit and Baseline in Soluble Intracellular Adhesion molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | ng/mL (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | -13.0 |
Glimepiride 2 mg and Metformin 850 mg BID | -3.2 |
The change between the value of Soluble Vascular Cell Adhesion Molecule collected at week 24 or final visit and Soluble Vascular Cell Adhesion Molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | ng/mL (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 11.6 |
Glimepiride 2 mg and Metformin 850 mg BID | 3.3 |
The change between Systolic Blood Pressure measured at week 24 or final visit and Systolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | mmHg (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | -2.5 |
Glimepiride 2 mg and Metformin 850 mg BID | 0.5 |
The change between the value of Thromboxane B2 collected at week 24 or final visit and Thromboxane B2 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | pg/mL (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | -216.4 |
Glimepiride 2 mg and Metformin 850 mg BID | 527.8 |
The change between the value of Triglycerides collected at week 24 or final visit and Triglycerides collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | mg/dL (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | -40.9 |
Glimepiride 2 mg and Metformin 850 mg BID | -16.7 |
The change between the value of Von-Willebrand Factor collected at week 24 or final visit and Von-Willebrand Factor collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | percent (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | -19.5 |
Glimepiride 2 mg and Metformin 850 mg BID | 1.4 |
The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | participants (Number) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 136 |
Glimepiride 2 mg and Metformin 850 mg BID | 137 |
The increase in High-Density Lipoprotein (HDL) Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
Intervention | mg/dL (Least Squares Mean) |
---|---|
Pioglitazone 15 mg and Metformin 850 mg BID | 3.2 |
Glimepiride 2 mg and Metformin 850 mg BID | -0.3 |
11 reviews available for pioglitazone and Dyslipidemias
Article | Year |
---|---|
Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Glucagon-Like Peptid | 2017 |
Pathophysiology of Diabetic Dyslipidemia.
Topics: Animals; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chylomicrons; Diabetes | 2018 |
Gender-specific risk factors for gout: a systematic review of cohort studies.
Topics: Age Factors; Animals; Body Size; Body Weight; Cohort Studies; Diabetes Complications; Diet; Diuretic | 2019 |
Nonalcoholic fatty liver disease: new treatments.
Topics: Antioxidants; Cardiovascular Diseases; Dyslipidemias; Humans; Hypoglycemic Agents; Insulin Resistanc | 2015 |
Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors.
Topics: Adipose Tissue; Apolipoproteins; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Humans; Hy | 2008 |
The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?
Topics: Biomarkers; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypoglycemic Agents; Lipoproteins, HDL | 2008 |
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type | 2009 |
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; H | 2010 |
Pioglitazone: a review of its use in type 2 diabetes mellitus.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drug T | 2006 |
The metabolic basis of atherogenic dyslipidemia.
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; D | 2005 |
[Therapy with glitazones--a risk for cardiovascular disease?].
Topics: Cardiovascular Diseases; Cholesterol, LDL; Contraindications; Diabetes Mellitus, Type 2; Dyslipidemi | 2007 |
16 trials available for pioglitazone and Dyslipidemias
Article | Year |
---|---|
Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; | 2020 |
Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Cardiovascular Diseases; Diabetes Mellitus, Type | 2017 |
Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia.
Topics: Adult; Aged; Body Mass Index; Body Weight; Dyslipidemias; Female; Gemfibrozil; Humans; Hypoglycemic | 2017 |
Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.
Topics: Adult; Biomarkers; Biopsy; Dyslipidemias; E-Selectin; Female; Humans; Intercellular Adhesion Molecul | 2019 |
Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue.
Topics: 3T3-L1 Cells; Adipocytes; Adult; Animals; Disease Models, Animal; Dyslipidemias; Fenofibrate; Humans | 2014 |
Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study.
Topics: Aged; Aged, 80 and over; Blood Pressure; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipid | 2014 |
No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
Topics: Aged; Animals; Aorta; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Vascu | 2014 |
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; | 2014 |
Withdrawal of pioglitazone in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Alkaline Phosphatase; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Sch | 2010 |
[Study of MDA-LDL by pioglitazone and pitavastatin in patients with type 2 diabetes].
Topics: Aged; Arteriosclerosis; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Ty | 2011 |
PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Topics: Adiponectin; Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; | 2011 |
Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; | 2005 |
Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.
Topics: Adolescent; Adult; Aged; Apolipoproteins; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholest | 2006 |
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Fatty Acids, Nonesterified; Glycated | 2007 |
The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Topics: Adult; Alkanesulfonates; Anticholesteremic Agents; Atorvastatin; Chemotherapy, Adjuvant; Cross-Over | 2007 |
The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Topics: Aged; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dru | 2008 |
16 other studies available for pioglitazone and Dyslipidemias
Article | Year |
---|---|
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
Topics: Animals; Blood Glucose; Butyric Acid; Cell Line; Cholesterol; Cricetinae; Diabetes Mellitus, Type 2; | 2009 |
Modulation of Insulin Resistance, Dyslipidemia and Serum Metabolome in iNOS Knockout Mice following Treatment with Nitrite, Metformin, Pioglitazone, and a Combination of Ampicillin and Neomycin.
Topics: Ampicillin; Animals; Drug Therapy, Combination; Dyslipidemias; Glucose; Homeostasis; Hypoglycemic Ag | 2021 |
Diabetes as First Manifestation of Autoimmune Pancreatitis.
Topics: Adrenal Cortex Hormones; Aged; Autoimmune Diseases; Diabetes Complications; Diabetes Mellitus; Dysli | 2017 |
Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: Involvement of CB2 and PPAR-γ receptors.
Topics: Animals; Diet; Dyslipidemias; Inflammation; Male; Pioglitazone; Polycyclic Sesquiterpenes; PPAR alph | 2019 |
Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats.
Topics: Animals; Aorta, Thoracic; Blood Glucose; Body Weight; C-Reactive Protein; Dyslipidemias; Fatty Liver | 2019 |
Non-glycemic effects of pioglitazone and incretin-based therapies.
Topics: Body Weight; Cardiovascular Diseases; Dyslipidemias; Humans; Hypoglycemic Agents; Incretins; Pioglit | 2013 |
Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Drug Resistance; Drug | 2014 |
Hyperinsulinaemic androgen excess in adolescent girls.
Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Human | 2014 |
A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor γ with Excellent Effect on Insulin Resistance and Type 2 Diabetes.
Topics: 3-Mercaptopropionic Acid; Animals; Blood Glucose; Cell Line; Cell Survival; Diabetes Mellitus, Exper | 2015 |
Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.
Topics: Aged; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Dise | 2008 |
Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone.
Topics: Animals; Blood Vessels; Disease Models, Animal; Disease Progression; Dyslipidemias; Hyperinsulinism; | 2011 |
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Topics: Animals; Apolipoprotein E2; Apolipoproteins E; Atherosclerosis; Blood Glucose; Disease Models, Anima | 2005 |
Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice.
Topics: Animals; Aorta, Thoracic; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; AT | 2006 |
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Carbazoles; Disease Models, Animal; Dyslipidemias; Gene Expr | 2006 |
Case report of Klinefelter's syndrome with severe diabetes, dyslipidemia, and stroke: The effect of pioglitazone and other anti-inflammatory agents on interleukin-6 and -8, tumor necrosis factor-alpha, and C-reactive protein.
Topics: Adult; Anti-Inflammatory Agents; C-Reactive Protein; Diabetes Mellitus; Dyslipidemias; Humans; Inter | 2006 |
[Determining the current position regarding the value of pioglitazone for the therapy of diabetes].
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fractures, Bone; Glycate | 2007 |